Key Points
- Insider sale: Suma Krishnan sold 25,000 shares on Dec. 4 at an average price of $220.16 for $5,504,000, reducing her stake by 1.74% to 1,413,711 shares, per an SEC Form 4 filing.
- Strong quarterly results: Krystal reported EPS of $2.66 (vs. $1.12 expected) and revenue of $97.8M (vs. $93.72M) with a 53.3% net margin, and analysts collectively rate the stock a "Moderate Buy" with a consensus target of $228.14.
- Market positioning: KRYS trades near its 52‑week high (opened $234.13), has a $6.79B market cap and a P/E of 35.1, and institutional investors own about 86.29% of the shares.
Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $220.16, for a total value of $5,504,000.00. Following the completion of the sale, the insider owned 1,413,711 shares of the company's stock, valued at approximately $311,242,613.76. This represents a 1.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Krystal Biotech Price Performance
Shares of Krystal Biotech stock opened at $234.13 on Friday. The business has a 50-day simple moving average of $197.92 and a 200 day simple moving average of $162.51. Krystal Biotech, Inc. has a one year low of $122.80 and a one year high of $234.65. The firm has a market capitalization of $6.79 billion, a price-to-earnings ratio of 35.10 and a beta of 0.48.
Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings data on Monday, November 3rd. The company reported $2.66 EPS for the quarter, beating analysts' consensus estimates of $1.12 by $1.54. The firm had revenue of $97.80 million during the quarter, compared to analysts' expectations of $93.72 million. Krystal Biotech had a return on equity of 19.36% and a net margin of 53.30%. On average, sell-side analysts expect that Krystal Biotech, Inc. will post 6.14 EPS for the current year.
Institutional Trading of Krystal Biotech
Several institutional investors have recently made changes to their positions in the company. CIBC Bancorp USA Inc. purchased a new position in shares of Krystal Biotech in the third quarter worth about $467,000. Wilmington Savings Fund Society FSB grew its position in Krystal Biotech by 78.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 393 shares of the company's stock worth $69,000 after acquiring an additional 173 shares during the last quarter. Danske Bank A S purchased a new position in Krystal Biotech in the 3rd quarter worth approximately $35,000. Advisory Services Network LLC bought a new stake in Krystal Biotech in the third quarter valued at approximately $151,000. Finally, CANADA LIFE ASSURANCE Co lifted its position in Krystal Biotech by 2.6% in the third quarter. CANADA LIFE ASSURANCE Co now owns 21,398 shares of the company's stock valued at $3,782,000 after purchasing an additional 551 shares during the last quarter. Institutional investors own 86.29% of the company's stock.
Wall Street Analysts Forecast Growth
Several analysts recently issued reports on the stock. Chardan Capital lifted their price target on shares of Krystal Biotech from $216.00 to $220.00 and gave the company a "buy" rating in a research report on Tuesday, November 4th. HC Wainwright reaffirmed a "buy" rating and issued a $240.00 price objective on shares of Krystal Biotech in a research note on Monday, September 15th. Guggenheim set a $224.00 target price on shares of Krystal Biotech and gave the stock a "buy" rating in a research report on Friday, October 17th. Weiss Ratings restated a "hold (c+)" rating on shares of Krystal Biotech in a report on Monday. Finally, Bank of America raised their price target on shares of Krystal Biotech from $182.00 to $255.00 and gave the company a "buy" rating in a research report on Friday, October 17th. Six equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat.com, Krystal Biotech has an average rating of "Moderate Buy" and a consensus target price of $228.14.
Read Our Latest Stock Report on KRYS
About Krystal Biotech
(
Get Free Report)
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
